Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellistem Lupus in Severe Renal SLE
NCT03917797Phase 2Recruiting
- Start
- Apr 2019
- Primary completion
- Dec 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of Cellistem Lupus in lupus nephritis (LN) (2 arms). Primary endpoint: Global Renal Response at 12 months. Started Apr 2019; status: recruiting.
02
Drugs
Cellistem Lupus
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT03917797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917797.